Article Per Year (5 Year)
p-Index From 2020 - 2025
2.93
P-Index
This Author published in this journals
All Journal Molecular and Cellular Biomedical Sciences (MCBS) Jurnal Respirologi Indonesia Jurnal Respirasi (JR) Sumatera Medical Journal AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh Respiratory Science Jurnal Impresi Indonesia The Journal of Society Medicine (JSOCMED)
Tarigan, Setia Putra
Division Of Thoracic Oncology, Department Of Pulmonology And Respiratory Medicine, Faculty Of Medicine, Universitas Sumatera Utara/Haji Adam Malik General Hospital, Medan, Indonesia.
Religion Biochemistry, Genetics & Molecular Biology Dentistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences

Published : 18 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Jurnal Respirasi (JR)

 1 
Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment Muhammad Harbi Praditya; Noni Novisari Soeroso; Setia Putra Tarigan; Taufik Ashar; Darren Wan-Teck Lim
Jurnal Respirasi Vol. 9 No. 1 (2023): January 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.1.2023.12-17

Abstract

Introduction: Patients with lung adenocarcinoma following epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment will develop acquired resistance after 7 to 16 months of starting the medication, indicated by the emergence of exon 20 T790M mutations. This study aimed to identify the clinical and demographical profile of acquired resistance in patients with lung adenocarcinoma receiving EGFR-TKI therapy through plasma circulating tumor deoxyribonucleic acid (ctDNA) examination. Methods: This was a descriptive study with a retrospective cross-sectional design involving 108 lung adenocarcinoma patients who received EGFR-TKI for more than six months. Exon 20 T790M EGFR mutations were identified as a sign of acquired resistance using the digital droplet polymerase chain reaction (ddPCR) approach to examine plasma ctDNA Utilizing the Statistical Package for the Social Sciences, statistical tests were used to examine the data (SPSS). The data were analyzed by statistical tests using the Statistical Package for the Social Sciences (SPSS). Results: A total of 31 patients were recruited as study participants. The majority of the research subjects were female (64.5%), aged 20-69 years old (58%), and non-smokers (67.7%). Exon 19 deletions were the most prevalent EGFR mutation (58.1%). The incidence of acquired resistance was found in 10 subjects (32.3%). Patients with acquired resistance were predominately female (70%), non-smokers (80%), and with gefitinib therapy (90%). The average time for EGFR-TKI treatment until acquired resistance occurred was 12.6 months. Conclusion: The incidence of acquired resistance was mainly found in women without a smoking history after 12.6 months of treatment with EGFR-TKI.
Deciphering the Coagulation Factors in Pulmonary Embolism Incident-Based Thorax Enhanced Chest CT in COVID-19 Patient Wan Betty Pratiwi; Noni Novisari Soeroso; Setia Putra Tarigan; Muntasir Abdullah; Rosita Juwita Sembiring; Azizah Ghanie Icksan; Netty Delvrita Lubis; Putri Chairani Eyanoer
Jurnal Respirasi Vol. 9 No. 2 (2023): May 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.2.2023.93-100

Abstract

Introduction: Pulmonary embolism is associated with coagulopathy in COVID-19. It is one of the causes of death in COVID-19 cases and is often underdiagnosed in Indonesia because computed tomography-pulmonary angiography (CTPA) is not used as the gold standard. T Methods: This study used a prospective analytical design with a cross-sectional approach. The study participants were 45 COVID-19 patients admitted to Santa Elisabeth Hospital, Medan, from January to March 2021.  Patients were identified with moderate to severe degrees of COVID-19 and elevated D-dimer and subsequently instructed to undergo a thorax CT scan with IV contrast. The data was analyzed using dependent t-test statistical analysis. The p-value < 0.05 was noted as significant. Results: Moderate to severe coagulation factor values in COVID-19 patients with mean + SD PT, APTT, D-dimer, fibrinogen, and platelets were 14.11; 30.65; 1172.14; 423.56 and 215.822, respectively. In this study, 22 (48.9%) patients experienced a pulmonary embolism, while the other 23 (51.1%) did not. No significant correlation was found between all coagulation factors and embolism (p > 0.05). The mean + SD well score for pulmonary embolism was 0.23 + 0.57. Conclusion: Pulmonary embolism was detected in 22 patients (48.49%) with moderate to severe COVID-19 who developed hypercoagulation as indicated by the thorax CT scan with IV contrast. This case was quite common. In resource-constrained situations, a thorax CT scan with IV contrast may replace CTPA in diagnosing/detecting the presence of pulmonary embolism.
Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment Stephen Johan Prasetyo; Noni Novisari Soeroso; Setia Putra Tarigan; Erna Mutiara; Novia Nurul Faizah
Jurnal Respirasi Vol. 9 No. 2 (2023): May 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.2.2023.101-107

Abstract

Introduction: Patients with adenocarcinoma of the lung that have a common EGFR mutation, the Exon 19 Del mutation, survive better than those with the Exon 21 L858R mutation. This study examined whether there is a significant difference in prognosis between two common EGFR mutations, namely exon 19 Del and 21 L858R. This study compared OS (overall survival) and PFS (progression-free survival) in NSCLC patients with Exon 19 Del and Exon 21 L858R mutations who received EGFR-TKI targeted therapy at H. Adam Malik Hospital Medan. Methods: This analysis study used a retrospective cohort design to evaluate the OS and PFS of NSCLC patients who underwent EGFR-TKI precision medicine at H. Adam Hospital Malik Medan between January 1, 2017, and December 31, 2020 and also had Exon 19 Del and Exon 21 L858R alterations. Results: A total of 88 people were sampled. The majority of research subjects were male (60.2%). Median OS was eleven months (95 percent CI:9.594-12,406). According to the study's data, eight people (9.1%) survived until the study's ending. The median OS of Exon 19 Del Common Mutation was 11 months (95%CI 9,064-12,936). While Exon 21 L858R group had ten months (95%CI 4,546-15,454). The log-rank test identified no statistical difference in median OS between mutation types (p=0.562). Conclusion: The findings of this study revealed that subjects with Exon 19 Del mutations had a longer median OS and PFS than those with Exon 21 L858R variants. Nevertheless, there was no significant difference in median OS and PFS between study subjects with mutation of Exon 19 Del and Exon 21 L858R, which received the targeted medication.
Co-Authors Arieta, Lydia Azizah Ghanie Icksan Buana, Indra Darren Wan-Teck Lim Dedy Dwi Putra, Dedy Dwi Dian Chayadi Elisna Syahruddin Elisna Syahruddin Elizabeth Napitupulu Erna Mutiara Erna Mutiara Erna Mutiara Evlin Suzanna Febiyanti, Mica Fotarisman Zalukhu Harahap, Putri Wulandari Hendra Taufik Hidayat Hidayat Lokman, Yovita Belva Lucia Aktalina Malisie, Ririe Fachrina Muhammad Harbi Praditya Muhammad Harbi Praditya Muntasir Abdullah Netty Delvrita Lubis Noni Novisari Soeroso Noni Novisari Soeroso Noni Novisari Soeroso Noni Novisari Soeroso Noni Novisari Soeroso Novia Nurul Faizah Novita Margaretta Ambarita Nurul Ramadhani Pinem, Agung Haganta Putri Chairani Eyanoer, Putri Chairani R.A Henny Anggriani Rahmat Hidayat Ritonga, Adewita Rosidah Hanum Hasibuan Rosita Juwita Sembiring Stephen Johan Prasetyo Tarigan, Amira P. Taufik Ashar Wan Betty Pratiwi Yahwardiah Siregar